GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chemomab Therapeutics Ltd (STU:2QV0) » Definitions » Cash Receipts from Fees and Commissions

Chemomab Therapeutics (STU:2QV0) Cash Receipts from Fees and Commissions


View and export this data going back to 2021. Start your Free Trial

What is Chemomab Therapeutics Cash Receipts from Fees and Commissions?

Cash Receipts from Fees and Commissions only applicable to companies reporting Cash Flow from Operations in direct method.


Chemomab Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
Kiryat Atidim, Building 7, Tel Aviv, ISR, 6158002
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.